Jolanda Howe Sells 926 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $86,423.58. Following the transaction, the senior vice president owned 3,042 shares of the company’s stock, valued at $283,909.86. The trade was a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $94.29 on Friday. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $4.85 billion, a P/E ratio of -109.64 and a beta of 0.48. The stock’s 50 day moving average is $77.33 and its 200 day moving average is $70.78. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.88 and a twelve month high of $96.84.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The business had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same quarter in the previous year, the business earned ($0.30) earnings per share. The firm’s quarterly revenue was up 47.1% compared to the same quarter last year. On average, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MIRM has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday. Morgan Stanley upped their target price on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $102.58.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. Sumitomo Mitsui Trust Group Inc. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $240,000. Wetzel Investment Advisors Inc. purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at $205,000. Palumbo Wealth Management LLC lifted its holdings in Mirum Pharmaceuticals by 19.8% in the fourth quarter. Palumbo Wealth Management LLC now owns 5,082 shares of the company’s stock valued at $401,000 after acquiring an additional 840 shares during the period. Secure Asset Management LLC boosted its position in Mirum Pharmaceuticals by 4.0% in the fourth quarter. Secure Asset Management LLC now owns 50,384 shares of the company’s stock worth $3,980,000 after purchasing an additional 1,943 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $1,478,000.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.